Posted byOrthoEx Posted in
Posted on May 11, 2018

May 10, 2018

SAN DIEGO–(BUSINESS WIRE)–DJO Global, Inc. (“DJO” or the “Company”), a leading global provider of medical technologies designed to get and keep people moving, today announced financial results for its public reporting subsidiary, DJO Finance LLC (“DJOFL”), for the first quarter ended March 31, 2018.

First Quarter Highlights

  • Net sales were $292.6 million, up 1.5% compared to the first quarter of 2017.
  • Operating income increased 501.9% to $33.5 million from $6.7 million in the prior year period.
  • Net loss attributable to DJOFL was $17.6 million, compared to a net loss of $40.0 million in the prior year period.
  • Adjusted EBITDA increased 13.2% over the prior year quarter to $64.8 million.

Business Transformation Outcomes

  • Business Transformation continues to drive profitability expansion and remains on track to deliver 7% to 10% annual cost reductions by end of 2018.
  • Transformation actions taken to date expected to contribute $21.8 million in savings over the next four quarters.

“After starting the quarter with slow revenue trends reflecting the overall market performance, we saw improvement later in the quarter, particularly in March. In line with our annual plan, we expect to build revenue momentum throughout the year as growth investments that began late in 2017 begin to materialize,” said Brady Shirley, DJO’s President and Chief Executive Officer. “Overall performance was highlighted by continued, strong earnings growth and significant margin expansion.”

“From a bottom-line perspective, we continue to demonstrate that our multi-year transformation is working, delivering 13% Adjusted EBITDA growth and over 200 basis point improvement in margin. The growth in Adjusted EBITDA is a product of improving gross margins and strong control of operating expenses, reflecting the hard work our team has put into our transformation initiatives,” commented Mike Eklund, DJO’s Chief Financial Officer and Chief Operating Officer. “Additional operations initiatives are already underway focused on enhancing customer satisfaction as well as financial metrics. We remain confident in our ability to continue the improvement we have seen since the start of this journey early last year.”

Sales Results

Net sales for DJOFL for the first quarter of 2018 were $292.6 million, an increase of 1.5% compared to the first quarter of 2017. On the basis of constant currency rates, sales declined 1.7%. The number of selling days in the first quarter of 2018 was unchanged from the prior year period in the US but there was one less selling day outside the US.

Net sales for DJO’s Surgical Implant segment grew 8.1% in the first quarter of 2018 to $53.6 million, reflecting greater than 20% growth in our large shoulder implant product line and single digit growth in our knee and hip implant product lines.

Net sales for DJO’s International segment grew 13.3% in the first quarter of 2018 to $88.6 million, or 1.5% on a constant currency basis with one less selling day. There was strong sales growth in France, Scandinavia and Australia, partially offset by slower sales in the UK, Spain and Benelux region.

Net sales for DJO’s Recovery Sciences segment were $35.9 million in the first quarter of 2018, down 6.8% compared to the first quarter of 2017, driven by softness in the segment’s Chattanooga product line.

Net sales for DJO’s Bracing and Vascular segment were $114.5 million in the first quarter of 2018, a decline of 6.2% compared to the first quarter of 2017, reflecting challenges in the segment’s Dr. Comfort product line and a decline in our US bracing business.

Earnings Results

Operating income improved to $33.5 million from $6.7 million in the prior year quarter, primarily due to a significant reduction in selling, general and administrative expenses. Net loss attributable to DJOFL in the first quarter of 2018 was $17.6 million compared to a net loss of $40.0 million for the first quarter of 2017.

Adjusted EBITDA for the first quarter of 2018 grew 13.2% to $64.8 million from $57.2 million in the first quarter of 2017. Including projected future savings of $21.8 million from cost savings programs currently underway as permitted under our credit agreement and the indentures governing our outstanding notes, Adjusted EBITDA for the twelve months ended March 31, 2018 was $297.5 million.

The Company defines Adjusted EBITDA as net (loss) income attributable to DJOFL plus net interest expense, income tax provision (benefit), and depreciation and amortization, further adjusted for certain non-cash items, non-recurring items and other adjustment items as permitted in calculating covenant compliance under the Company’s secured term loan and revolving credit facilities (“Senior Secured Credit Facilities”) and the indentures governing its 8.125% second lien notes and its 10.75% third lien notes. A reconciliation between net loss attributable to DJOFL and Adjusted EBITDA is included in the attached financial tables.

Net cash provided by continuing operating activities for the first quarter of 2018 was $12.2 million compared to $38.6 million in the first quarter of 2017. The decline in cash flow was attributable to higher inventory balances to allow for the transition of suppliers and modernization of distribution facilities as part of the Company’s transformation initiative, and to the payment of one-time costs accrued in the prior year.

Conference Call Information

DJO has scheduled a conference call to discuss this announcement beginning at 4:30 pm, Eastern Time Thursday, May 10, 2018. Individuals interested in listening to the conference call may do so by dialing (866) 394-8509 (International callers please use (706) 643-6833), using the reservation code 22322226. A telephone replay will be available for 48 hours following the conclusion of the call by dialing (855) 859-2056 and using the above reservation code. The live conference call and replay will be available via the Internet at

About DJO Global

DJO Global is a leading global provider of medical technologies designed to get and keep people moving. The Company’s products address the continuum of patient care from injury prevention to rehabilitation, enabling people to regain or maintain their natural motion. Its products are used by orthopaedic surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers and other healthcare professionals. In addition, many of the Company’s medical devices and related accessories are used by athletes and patients for injury prevention and at-home physical therapy treatment. The Company’s product lines include rigid and soft orthopaedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators used for pain management and physical therapy products. The Company’s surgical division offers a comprehensive suite of reconstructive joint products for the hip, knee and shoulder. DJO Global’s products are marketed under a portfolio of brands including Aircast®, Chattanooga, CMF™, Compex®, DonJoy®, ProCare®, DJO® Surgical, Dr. Comfort® and ExosTM. For additional information on the Company, please visit

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements relate to, among other things, the Company’s expectations for improved liquidity, estimated cost reductions associated with the execution of its business transformation plans and improved efficiencies. The words “believe,” “will,” “should,” “expect,” “target,” “intend,” “estimate” and “anticipate,” variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based on the Company’s current expectations and are subject to a number of risks, uncertainties and assumptions, many of which are beyond the Company’s ability to control or predict. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. The important factors that could cause actual operating results to differ significantly from those expressed or implied by such forward-looking statements include, but are not limited to the successful execution of the Company’s business transformation plans, including achievement of planned actions to improve liquidity, improvements in operational effectiveness, optimization of the Company’s procurement activities, improvements in manufacturing, distribution, sales and operations planning, and actions to improve the profitability of the mix of our product and customers. Other important factors that could cause actual operating results to differ significantly from those expressed or implied by such forward-looking statements include, but are not limited to: business strategies relative to our Bracing and Vascular, Recovery Sciences, International and Surgical Implant segments; the continued growth of the markets the Company addresses and any impact on these markets from changes in global economic conditions; the impact of potential reductions in reimbursement levels and coverage by Medicare and other governmental and commercial payers; the Company’s highly leveraged financial position; the Company’s ability to successfully develop, license or acquire, and timely introduce and market new products or product enhancements; risks relating to the Company’s international operations; resources needed and risks involved in complying with government regulations and government investigations; the availability and sufficiency of insurance coverage for pending and future product liability claims; and the effects of healthcare reform, Medicare competitive bidding, managed care and buying groups on the prices of the Company’s products. These and other risk factors related to DJO are detailed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, filed with the Securities and Exchange Commission on March 16, 2018. Many of the factors that will determine the outcome of the subject matter of this press release are beyond the Company’s ability to control or predict.

DJO Finance LLC
Unaudited Condensed Consolidated Statements of Operations
(In thousands)

Three Months Ended
March 31,


April 1,


Net sales $ 292,629 $ 288,389
Operating expenses:
Cost of sales (exclusive of amortization of intangible assets of $6,658 and $6,981 for three months ended March 31, 2018 and April 1, 2017, respectively) 119,936 119,569
Selling, general and administrative 115,316 134,162
Research and development 9,282 9,139
Amortization of intangible assets 14,598 18,845
259,132 281,715
Operating income 33,497 6,674
Other (expense) income:
Interest expense, net (43,922 ) (42,687 )
Other (expense) income, net (1,540 ) 288
(45,462 ) (42,399 )
Loss before income taxes (11,965 ) (35,725 )
Income tax provision (5,385 ) (4,078 )
Net loss from continuing operations (17,350 ) (39,803 )
Net income from discontinued operations 144 58
Net loss (17,206 ) (39,745 )
Net income attributable to noncontrolling interests (362 ) (224 )
Net loss attributable to DJO Finance LLC $ (17,568 ) $ (39,969 )